

cgc

Patent No. : 6,887,893 B1  
Patentee : Kurakata et al  
Issued : May 3, 2005  
Serial No. : 09/212,556  
Filed : December 16, 1998  
For : METHODS AND COMPOSITIONS  
FOR TREATMENT AND  
PREVENTION OF TUMORS,...  
Docket No. : 980689/HG

**REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR 1.322**

Hon. Commissioner of Patents

S I R :

It is respectfully requested that a Certificate of Correction be issued to correct the error in the printing of the patent. The error to be corrected is indicated on the enclosed Patent Office form PTO/SB/44.

With regard to the corrections to be made on the Title Page, attention is directed to the Office Action dated April 10, 2001, and to the attached Notice of References Cited, and to the INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 dated June 28, 1999, January 4, 2000, August 1, 2000, August 29, 2000 and February 7, 2001 which were attached to said Office Action of April 10, 2001 and which contain the Examiner's initials in the left margin evidencing that they were considered and made of record.

**CERTIFICATE OF MAILING**

I hereby certify this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date noted below.

  
Attorney: Herbert Goodman


**Certificate**  
Dated: May 16, 2007  
**MAY 24 2007**  
**of Correction**

**MAY 25 2007**

With regard to the corrections to be made in column 34, patent claim 4 is identical to patent claim 2; patent claims 5 is identical to patent claim 3. The enclosed copy of the ISSUE CLASSIFICATION form shows that patent claim 4 was application claim 76, and patent claim 5 was application claim 77. Said ISSUE CLASSIFICATION form also shows that application claims 71 and 72 were cancelled. Applicants' AMENDMENT UNDER 37 CFR 1.312 filed September 22, 2004 included instructions to cancel claims 71, 72, 76 and 77. The fact that said AMENDMENT UNDER CFR 1.312 was entered and acted upon is established by the cancellation of claims 71 and 72. It was a PTO error not to also follow the instructions in the same AMENDMENT UNDER 37 CFR 1.312 to cancel application claims 76 and 77.

Favorable action is solicited.

Respectfully submitted,

  
HERBERT GOODMAN  
Reg. No. 17,081

Frishauf, Holtz, Goodman,  
& Chick, P.C.  
220 Fifth Avenue - 16<sup>th</sup> Floor  
New York, NY 10001-7708  
Telephone: (212) 319-4900  
Facsimile: (212) 319-5101  
HG/fs

MAY 25 2007

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 3 Pages

PATENT NO. : 6,887,893 B1  
DATED : May 3, 2005  
INVENTOR(S) : Kurakata et al

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page, Left Column, (56) **References Cited**, under U.S. PATENT DOCUMENTS insert

- -	4,962,119	10/1990	Boschelli et al
	5,466,823	11/1995	Talley et al
	5,550,142	8/1996	Ducharme et al
	5,972,986	10/1999	Seibert et al - -;

under FOREIGN PATENT DOCUMENTS insert

- -	EP	0688723 A1	10/1997
	EP	0745596 A	12/1996
	EP	0863134 A	9/1998
	WO	WO 92/10190	6/1992
	WO	WO 92/10498	6/1992
	WO	WO 94/13635	6/1994
	WO	WO 95/18799	7/1995
	WO	WO 95/32194	11/1995
	WO	WO 98/06708	2/1998 - -;

## MAILING ADDRESS OF SENDER:

Herbert Goodman, Esq.  
Frishauf, Holtz, Goodman & Chick, P.C.  
220 Fifth Ave., New York, NY 10001-7708

PATENT NO. 6,887,893 B1

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

May 25 2004

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 2 of 3 Pages

PATENT NO. : 6,887,893 B1  
DATED : May 3, 2005  
INVENTOR(S) : Kurakata et al

It is certified that error appears in the above-identified patent and that said Letters Patent  
is hereby corrected as shown below:

under OTHER PUBLICATIONS insert

- - \* Strelkov et al, "Effects of systemic...", *Am. J. Physiol.*,  
vol. 257, pp. C261-67, (1989).

J.J. Li et al, "1,2-Diarylcyclopentenones as selective  
cyclooxygenase-2 inhibitors and orally active anti-inflammatory  
agents", *Journal of Medicinal Chemistry*, vol. 38, No. 22,  
pp. 4570-4578 (Oct. 1995).

N. Futaki et al, "NS-398, A new anti-inflammatory agent,  
selectively inhibits prostaglandin G/H synthase/cyclooxygenase  
(COX-2) activity in vitro", *Prostaglandins*, vol. 47, pp. 55-59  
(Jan 1994).

K. Tanaka et al, "T-614, A novel antirheumatic drug, inhibits  
both the activity and induction of cyclooxygenase-2 (COX-2) in  
cultured fibroblasts", *Japanese Journal of Pharmacology*, vol. 67,  
No. 4, pp. 305-314 (April 1995).

**MAILING ADDRESS OF SENDER:**

Herbert Goodman, Esq.  
Frishauf, Holtz, Goodman & Chick, P.C.  
220 Fifth Ave., New York, NY 10001-7708

PATENT NO. 6,887,893 B1

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Y 25 2007

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 3 of 3 Pages

PATENT NO. : 6,887,893 B1  
DATED : May 3, 2005  
INVENTOR(S) : Kurakata et al

It is certified that error appears in the above-identified patent and that said Letters Patent  
is hereby corrected as shown below:

Oshima et al, "Suppression of intestinal polyposis in *Apc*<sup>A716</sup>  
knockout mice by inhibition of cyclooxygenase 2 (COX-2)", *Cell*,  
vol. 87, pp. 803-809, (November 29, 1996).

Teicher et al, "Cyclooxygenase and lipoxxygenase inhibitors as  
modulators of cancer therapies", *Cancer Chemother Pharmacol*,  
vol. 33, pp. 515-522 (1994).

Tsujii M. et al, "Cyclooxygenase-2 expression in human colon  
cancer cells increases metastatic potential", *Proc. Natl. Acad.  
Sci. USA* 1997, April 1; 94(7), B9533, 36-40, Abstract, Medline  
(on-line) Department of Medicine USA, No. 97250538.

Ristimakia et al, "Expression of cyclooxygenase-2 in human  
gastric carcinoma", *Cancer, Res.*, 1997 April 1; 57(7), 1276-80,  
Abstract, Medline (on-line) Department of Medicine USA. - -.

\* Cited by Examiner

Column 34, lines 15-17 (Claim 4): Delete in entirety.

Column 34, lines 18-20 (Claim 5): Delete in entirety.

**MAILING ADDRESS OF SENDER:**

Herbert Goodman, Esq.  
Frishauf, Holtz, Goodman & Chick, P.C.  
220 Fifth Ave., New York, NY 10001-7708

PATENT NO. 6,887,893 B1

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAY 25 2007



### ISSUE CLASSIFICATION

U.S. Patent and Trademark Office

Part of Paper No. 000

MAY 25 2007.

25 2007